This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
11 Aug 2011

Kamada Gets ODD from FDA for Type 1 Diabetes Treatment

FDA grants an orphan drug designation for Kamada's Alpha-1 Antitrypsin drug to treat type 1 diabetes.

Biopharmaceutical company Kamada has received an orphan drug designation (ODD) from the US FDA for its Alpha-1 Antitrypsin (AAT) drug to treat type 1 diabetes.

 

The company is currently undergoing a Phase I/II clinical trial with AAT by IV route of administration.

 

AAT IV was granted FDA approval in July 2010 for the treatment of Alpha 1 deficiency and is exclusively marketed by Baxter in the US.

 

Kamada's next-generation AAT by inhalation is currently undergoing a Phase 2-3 trial in Europe. The company has already completed five clinical trials with its high purity, liquid formulation of inhaled Alpha-1 Antitrypsin.

Related News